Howe & Rusling’s Iovance Biotherapeutics IOVA Stock Holding History

Howe & Rusling’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-98	Closed	-$1K	–	663
2022 Q3	$1K	Buy	+98	New	+$1.13K	﹤0.01%	968

Other funds holding IOVA

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MFM

MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Howe & Rusling's IOVA Position: Q4 2022 in Review

Howe & Rusling sold out of Iovance Biotherapeutics (IOVA) in Q4 2022, closing a stake of 98 shares — an estimated $1K sold.

Howe & Rusling first reported a position in IOVA in Q3 2022 and held it in 1 quarter. The position peaked at $1K in Q3 2022. 218 funds tracked by Wall St. Rank hold IOVA as of Q4 2022.

Howe & Rusling reported no remaining Iovance Biotherapeutics position as of Q4 2022 after selling out during the quarter.
Howe & Rusling sold 98 Iovance Biotherapeutics shares in Q4 2022, an estimated $1K.
Howe & Rusling first reported a position in Iovance Biotherapeutics in Q3 2022 and held it in 1 quarter.
Howe & Rusling's Iovance Biotherapeutics position peaked at $1K in Q3 2022.
218 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2022.

Based on Howe & Rusling's 13F filing for Q4 2022, filed 15 Feb 2023.